Antibody optimization is an important area of research because it has the potential to improve the effectiveness of antibodies, which are important tools for fighting diseases. Antibodies are proteins produced by the immune system that is able to recognize and bind to specific molecules, such as viruses and bacteria. By optimizing the properties of antibodies, researchers can improve their ability to bind to their targets and make them more effective at neutralizing diseases.

GenScript ProBio is a full-service CRO providing GMP source plasmid DNA services using GenScript GMPro plasmid DNA. Our plasmid production services are appropriate for the production of viral vectors or mRNA therapeutics.

GenScript ProBio is dedicated to providing a one-stop solution from plasmid production to viral vector production (Lentiviral vector or AAV) to Global clients from China, USA, Korea, etc.

Antibody humanization & antibodies characterization can reduce the immunogenicity of monoclonal antibodies derived from xenogeneic sources. At GenScript ProBio, we offer two different packages for our antibody humanization services - deluxe and express. Our deluxe package uses CDR-grafting, back mutation with PTM analysis and screening with FASEBA to screen for the humanized antibody with the best affinity.

Plasmid DNA manufacturing is the core of viral and mRNA vector generation. Plasmid DNA encodes for the production of viral and mRNA vectors, which are used to insert genetic material into cells. Biologics manufacturing services are also used for the replication of these vectors.

Pharmacokinetic analysis of antibodies or PK analysis service is a process of determining the movement of antibodies through the body. This process can be used to assess the efficacy of a new antibody drug or to monitor the levels of antibodies in the body during treatment.

When combined with modern technology for gene expression including cells-specific promoters as well as the Cre/lox system and genome-editing, AAVs provide a feasible quick, cost-effective, and affordable alternative to conditional knockouts or the transgenic mice models. But, there are many obstacles to widespread AAV cell line use, including ineffective methods for purification and small viral numbers. We present an improved procedure to make AAVs with serotypes that are not dependent on their genotypes.

GenScript ProBio is dedicated to developing technologies in adherent lentivirus production and manufacturing viral vectors for researchers to satisfy needs from preclinical through clinical to commercialization. Currently, GenScript ProBio has established a robust platform to manufacture Lentiviral vectors, using either adherent or suspension culture for lentivirus production.

The Food and Drug Administration’s Investigational New Drug( IND) program is the method that which a pharmaceutical company is granted permission to transport an experimental drug over states (usually to clinical researchers) before the time a marketing request for the drug is approved. The FDA evaluates the IND-enabling services. For safety to ensure that research subjects are not placed at risk in any way. When the application has been approved the drug candidate typically is placed in an initial clinical trial.